
FOR IMMEDIATE RELEASE

**License, Distribution and Supply Agreement to market
Cholecalciferol in China, Hong Kong, Macau and Taiwan**

Hong Kong, 8 September 2014 - Lee's Pharmaceutical Holdings Limited ("the Group" or "Lee's") (Main Board Stock Code: 0950; Website: www.leespharm.com) and Abiogen Pharma S.p.A. of Pisa, Italy today jointly announced the signing of an agreement for License, Distribution and Supply for marketing of **Thorens® Cholecalciferol (or vitamin D3)** throughout China, Hong Kong, Macau and Taiwan.

Under the terms of this agreement, Abiogen granted Lee's an exclusive license and right for registering, importing, marketing, distributing and selling the Cholecalciferol finished products (oral drops, oral solution and solution for injection) in the territory, for the prevention and treatment of vitamin D deficiency.

Cholecalciferol (or vitamin D3) is a natural compound synthesized by the skin under strong summer sun and utilized by the human body on a need basis. It is now regarded as an essential molecule with hormone-like activities coordinating various physiological functions, in addition to its classical activity in bone mineralization process. In the normal population, limitations to natural vitamin D formation are insufficient exposure to strong sunlight, age, skin pigmentation, sun-screen and clothing use, use of concomitant medications and certain disease conditions. On an average more than half of total world population today show insufficient vitamin D level in the body. Vitamin D deficiency may cause serious life-threatening conditions, if left untreated. The most efficient way to replenish the reservoirs and maintain normal vitamin D values is to supplement Vitamin D exogenously in man.

"We are excited to expand our partnership with Abiogen Pharma in this important area of bone metabolism," said Dr. Benjamin Li, Chief Executive Officer. "Vitamin D deficiency is a growing problem, especially in patients on dialysis. The availability of Cholecalciferol will certainly strengthen Lee's Pharmaceutical's presence in dialysis area where the Group's leading product – Carnitine, has been helping the improvement of quality of life of dialysis patient."

Dr. Massimo Di Martino, President & CEO of Abiogen Pharma said "I am very pleased to extend for the second time our strategic collaboration to valorize Lee's capacities in Hong Kong, China and other countries." He said "Deficiency of vitamin D is a Global Silent Epidemic. We have the means to address this threat and we should start in the most populated countries of the world."



FOR IMMEDIATE RELEASE

About Abiogen Pharma

Abiogen Pharma is a privately owned specialist pharmaceutical company focused on bone metabolism and some rare diseases. The Company was founded in 1997 as a spin-off of Istituto Gentili. Abiogen employs about 330 people with its headquarters in Pisa, Italy. The team of R&D of Abiogen Pharma had developed and continues to develop several bisphosphonates, including ethidronate, alendronate, clodronate and neridronate. For more information, please visit www.abiogen.it.

Abiogen Pharma started a strategic collaboration with Lee's Pharmaceutical in May 2014 on ATTILA® (neridronic acid) for the treatment of two rare diseases: Osteogenesis imperfecta and Complex Regional Pain Syndrome type 1 (CRPS-1). THORENS® is the second strategic collaboration between the Companies.

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a research-based Hong Kong biopharmaceutical company with 20 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.

About Cholecalciferol

Since the first registration in Italy in 2005, Abiogen Pharma is recognized as a leader in vitamin D market with Dibase® (Italy) and Thorens® (international) brands managing the "Global Silent Epidemic". Both are leading prescription medicines that naturally restore vitamin D levels, thanks to the physiological mode of action of cholecalciferol. The products are currently authorized for the prevention and treatment of vitamin D deficiency in many countries.

FOR IMMEDIATE RELEASE

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: +852 2314-1282

Fax: +852 2314-1708

Email: info@leespharm.com

Mithu Sen

Tel: +39 050 3154 273

Email: mithu.sen@abiogen.it

Fabrizio Nannipieri

Tel: +39 050 3154 289

Email: fabrizio.nannipieri@abiogen.it